These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32663199)

  • 1. Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies.
    Shah HB; Smith K; Scott EJ; Larabee JL; James JA; Ballard JD; Lang ML
    JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32663199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B.
    Devera TS; Lang GA; Lanis JM; Rampuria P; Gilmore CL; James JA; Ballard JD; Lang ML
    Infect Immun; 2016 Jan; 84(1):194-204. PubMed ID: 26502913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridioides difficile Infection Induces an Inferior IgG Response to That Induced by Immunization and Is Associated with a Lack of T Follicular Helper Cell and Memory B Cell Expansion.
    Amadou Amani S; Shadid T; Ballard JD; Lang ML
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31871095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Murine Neonatal Fc Receptor Is Required for Transport of Immunization-Induced C. difficile-Specific IgG to the Gut and Protection against Disease but Does Not Affect Disease Susceptibility.
    Amadou Amani S; Lang GA; Ballard JD; Lang ML
    Infect Immun; 2021 Sep; 89(10):e0027421. PubMed ID: 34097471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection.
    Rigo I; Young MK; Abhyankar MM; Xu F; Ramakrishnan G; Naz F; Madden GR; Petri WA
    Anaerobe; 2024 Jun; 87():102842. PubMed ID: 38552897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.
    Larabee JL; Krumholz A; Hunt JJ; Lanis JM; Ballard JD
    J Biol Chem; 2015 Mar; 290(11):6975-85. PubMed ID: 25614625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy induced by recombinant Clostridium difficile toxin fragments.
    Leuzzi R; Spencer J; Buckley A; Brettoni C; Martinelli M; Tulli L; Marchi S; Luzzi E; Irvine J; Candlish D; Veggi D; Pansegrau W; Fiaschi L; Savino S; Swennen E; Cakici O; Oviedo-Orta E; Giraldi M; Baudner B; D'Urzo N; Maione D; Soriani M; Rappuoli R; Pizza M; Douce GR; Scarselli M
    Infect Immun; 2013 Aug; 81(8):2851-60. PubMed ID: 23716610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive immune response to Clostridium difficile infection: A perspective for prevention and therapy.
    Rees WD; Steiner TS
    Eur J Immunol; 2018 Mar; 48(3):398-406. PubMed ID: 29272036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
    Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
    Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.
    Norman KM; Lang GA; Shadid TM; Honold ST; Reel JM; Cox MA; Ballard JD; Lang ML
    Cell Rep; 2024 May; 43(5):114245. PubMed ID: 38761377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
    Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
    J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent Clostridioides difficile Infection Is Associated With Impaired T Helper Type 17 Immunity to C difficile Toxin B.
    Cook L; Rees WD; Wong MQ; Kwok WW; Levings MK; Steiner TS
    Gastroenterology; 2021 Mar; 160(4):1410-1413.e4. PubMed ID: 33253683
    [No Abstract]   [Full Text] [Related]  

  • 15. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.
    Gilbert J; Leslie J; Putler R; Weiner S; Standke A; Penkevich A; Keidan M; Young VB; Rao K
    Anaerobe; 2021 Feb; 67():102299. PubMed ID: 33227427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
    Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
    Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B.
    Chen W; Liu WE; Li YM; Luo S; Zhong YM
    Mol Med Rep; 2015 Nov; 12(5):7712-20. PubMed ID: 26459027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.